Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gabapentin + sufentanil
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous (for Sufentanil), Other Parenteral Routes (for Sufentanil)
01
Overview
Gabapentin + sufentanil is a combination of two pharmaceutical agents used primarily for pain management. Gabapentin is an anticonvulsant and neuropathic pain agent that modulates the activity of voltage-gated calcium channels, thereby reducing excitatory neurotransmitter release in the central nervous system. Sufentanil is a potent synthetic opioid analgesic that acts as an agonist at the mu-opioid receptor, providing strong analgesia. The combination may be used perioperatively or for severe pain where multimodal analgesia is desired to enhance efficacy and reduce opioid requirements.
- Other names
- 加巴喷丁 + 舒芬太尼
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)CACNA2D2 (α2δ-2)MOR (Mu opioid receptor)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on gabapentin + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gabapentin + sufentanil.